Cagrilintide/GLP-1 Blend research peptide vial
RUO
Peptide Blends

Cagrilintide/GLP-1 Blend

Cagrilintide / GLP-1 Receptor Agonist Blend

Purity 98%+
Form Lyophilized Powder
Molecular Weight Blend - varies by component
CAS Number See COA
Dosage: Blend
Also known as: CagriSema Blend, Amylin/GLP-1 Blend
Sequence: Blend - Cagrilintide (amylin analogue) and GLP-1 agonist
Research Areas
Metabolic Research Obesity Dual Hormone Agonism Appetite Regulation
Buy at Research Vials

Overview

This blend combines cagrilintide, a long-acting amylin receptor agonist, with a GLP-1 receptor agonist. The combination targets two distinct but complementary appetite-regulation pathways, based on the same pharmacological principle behind Novo Nordisk's CagriSema development program. Cagrilintide is an acylated analogue of amylin, a hormone co-secreted with insulin from pancreatic beta cells after meals. Amylin acts on the area postrema and nucleus tractus solitarius in the brainstem to promote satiety, slow gastric emptying, and suppress postprandial glucagon secretion. Native amylin has a half-life of only 13 minutes; cagrilintide's fatty acid acylation enables weekly dosing through albumin binding. The GLP-1 component activates a parallel appetite-suppression pathway: GLP-1 receptors in the hypothalamus and brainstem mediate satiety signaling, glucose-dependent insulin secretion, and reduced gastric motility. Phase II data from the CagriSema development program showed the combination of cagrilintide + semaglutide produced approximately 15-17% body weight reduction at 32 weeks — numerically greater than either component alone — suggesting additive or synergistic effects between the amylin and GLP-1 pathways.

Mechanism of Action

This blend combines cagrilintide, a long-acting amylin receptor agonist, with a GLP-1 receptor agonist. The combination targets two distinct but complementary appetite-regulation pathways, based on the same pharmacological principle behind Novo Nordisk's CagriSema development program. Cagrilintide is an acylated analogue of amylin, a hormone co-secreted with insulin from pancreatic beta cells after meals. Amylin acts on the area postrema and nucleus tractus solitarius in the brainstem to promote satiety, slow gastric emptying, and suppress postprandial glucagon secretion. Native amylin has a half-life of only 13 minutes; cagrilintide's fatty acid acylation enables weekly dosing through albumin binding. The GLP-1 component activates a parallel appetite-suppression pathway: GLP-1 receptors in the hypothalamus and brainstem mediate satiety signaling, glucose-dependent insulin secretion, and reduced gastric motility. Phase II data from the CagriSema development program showed the combination of cagrilintide + semaglutide produced approximately 15-17% body weight reduction at 32 weeks — numerically greater than either component alone — suggesting additive or synergistic effects between the amylin and GLP-1 pathways.

Key Research Findings

  • Lau et al. (2021) demonstrated cagrilintide produced dose-dependent weight loss up to 10.8% at 26 weeks in adults with overweight or obesity in a Phase II trial.
  • Enebo et al. (2021) showed the combination of cagrilintide and semaglutide (CagriSema) produced greater weight loss than either agent alone in a Phase Ib trial.
  • Lutz & Bhatt (2022) reviewed the rationale for dual amylin/GLP-1 agonism, noting that amylin and GLP-1 activate distinct but convergent satiety circuits in the brainstem.
  • Hay et al. (2015) characterized the amylin receptor system and its role in energy balance regulation.

Citations & References

1

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Lau DCW, Erichsen L, Francisco-Ziller N, et al. — Lancet (2021)

2

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management

Enebo LB, Berthelsen KK, Kankam M, et al. — Lancet (2021)

3

Amylin: pharmacology, physiology, and clinical potential

Hay DL, Chen S, Lutz TA, et al. — Pharmacol Rev (2015)

Dosage in Research

Clinical trials of cagrilintide used 1.2-4.5 mg weekly SC. CagriSema trials combined cagrilintide 2.4 mg + semaglutide 2.4 mg weekly. Blend ratios in research products may vary.

Dosage information is derived from published research literature and is presented for educational purposes only. This is not medical advice. All products are for laboratory research use only.

Storage & Handling

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.

Frequently Asked Questions

What is Cagrilintide/GLP-1 Blend?
A combination of the amylin analog Cagrilintide with a GLP-1 agonist, investigated for dual-pathway effects on satiety signaling and metabolic regulation.
What purity is your Cagrilintide/GLP-1 Blend?
Our Cagrilintide/GLP-1 Blend is manufactured at 98%+ purity, verified through third-party HPLC analysis and mass spectrometry. A Certificate of Analysis (COA) is included with every order.
How should I store Cagrilintide/GLP-1 Blend?
Store lyophilized powder in a cool, dry place at 2-8°C away from direct light. Once reconstituted, refrigerate and use within the timeframe specified on the COA.
Is Cagrilintide/GLP-1 Blend for human use?
No. Cagrilintide/GLP-1 Blend is sold strictly for laboratory research use only. It is not intended for human consumption, veterinary use, or as a food additive. Products have not been evaluated by the FDA. Purchasers must be 21+ and confirm research use intent.
Where can I buy Cagrilintide/GLP-1 Blend?
Cagrilintide/GLP-1 Blend is available for purchase at researchvials.com. All orders include a COA and ship with temperature-controlled packaging.

Research Use Only

All products are intended for laboratory research and educational purposes only. Products have not been evaluated by the FDA and are not intended for human consumption, diagnosis, treatment, or prevention of any disease. Purchasers must be 21+ and confirm research use intent.